<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01944371</url>
  </required_header>
  <id_info>
    <org_study_id>13-10948</org_study_id>
    <secondary_id>DAIDS-ES ID 11864</secondary_id>
    <secondary_id>K24AI069994</secondary_id>
    <nct_id>NCT01944371</nct_id>
  </id_info>
  <brief_title>Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study</brief_title>
  <official_title>Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>amfAR, The Foundation for AIDS Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, pharmacology and bioactivity of
      disulfiram in antiretroviral treated HIV-infected adults. The investigators primary
      hypothesis is that 3 days of disulfiram will result in an increase in HIV transcription in
      CD4+ T-cells in patients on suppressive antiretroviral therapy (ART).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combination antiretroviral therapy for HIV-1 infection can suppress viremia to below the
      detection limit in the vast majority of motivated individuals with access to these drugs.
      However, HIV-1 persists in a small pool of latently infected resting memory CD4+ T cells
      carrying integrated viral genomes. Although other reservoirs for HIV-1 exist, the general
      consensus among experts is that latent virus (HIV DNA in resting memory CD4+ T cells) is the
      primary barrier to HIV-1 eradication. A widely discussed approach for eliminating this viral
      reservoir requires reactivation of latent HIV-1. Disulfiram, an FDA-approved drug used to
      treat alcoholism was shown to activate HIV-1 gene expression in vitro, suggesting that
      activation of latently infected cells in vivo may occur. Our primary hypothesis is that the
      addition of disulfiram to a stable effective antiretroviral drug regimen will result in a
      dose dependent increase in HIV transcription in CD4+ T-cells in HIV-1 in patients on highly
      active antiretroviral therapy (HAART).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cell-associated HIV RNA</measure>
    <time_frame>Baseline and 3 days</time_frame>
    <description>Fold change cell-associated HIV RNA in Total CD4 T-Cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV RNA</measure>
    <time_frame>Baseline and 3 days</time_frame>
    <description>Fold change in plasma HIV RNA levels from baseline through day 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proviral HIV DNA</measure>
    <time_frame>Baseline and 30 days</time_frame>
    <description>Fold change in HIV DNA levels between Baseline and Day 30</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Disufiram Pharmacokinetics</measure>
    <time_frame>31 days</time_frame>
    <description>Plasma concentrations of disulfiram were measured on dosing day 1 (hours 0, 2, and 6), day 2 (hour 0), and day 3 (hours 0, 2, and 6), as well as on postdosing days 4, 8, and 31. The area under the curve (AUC) levels over 72 hours was estimated.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>HIV</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>disulfiram 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500mg disulfiram by mouth per day for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>disulfiram 1000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000mg disulfiram by mouth per day for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>disulfiram 2000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2000mg disulfiram per mouth per day for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Disulfiram</intervention_name>
    <description>This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
    <arm_group_label>disulfiram 1000mg</arm_group_label>
    <arm_group_label>disulfiram 2000mg</arm_group_label>
    <arm_group_label>disulfiram 500mg</arm_group_label>
    <other_name>Antabuse,NDC 0093-5036-01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection

          -  Age 18 or older

          -  HIV plasma viral load &lt;50 copies/ml for at least 3 years with at least one measurement
             per year and most recent viral load within 3 months of screening.

          -  Receiving combination antiretroviral therapy (at least 3 agents); subjects must be on
             a efavirenz-based or a ritonavir-based regimen

          -  Two CD4+ T cell counts greater than 350 cell/Âµl in the six months prior to screening

          -  Willing to abstain from any alcohol one day before, during the three day period in
             which disulfiram will be administered and the two week period immediately after
             disulfiram administration

        Exclusion Criteria:

          -  Current alcohol use disorder or hazardous alcohol use

          -  Current use of any drug formulation that contains alcohol or that might contain
             alcohol, including the gelatin capsule and liquid formulations of ritonavir,
             ritonavir/lopinavir, amprenavir and fosamprenavir.

          -  Current use of tipranavir or maraviroc.

          -  Current use of zidovudine, stavudine or didanosine (as disulfiram potentially has
             potent irreversible inhibitory effects on mitochondrial metabolism and hence could
             exacerbate the toxicity of these drugs).

          -  Concurrent use of rivaroxaban ( a CYP3A metabolized medication) as the cytochrome P450
             inhibitory effects of disulfiram on rivaroxaban are unknown.

          -  Current use of warfarin

          -  Patients who are intending to modify antiretroviral therapy in the next 2 weeks for
             any reason.

          -  Serious illness requiring hospitalization or parental antibiotics within preceding 3
             months

          -  A screening hemoglobin below 12.5 g/dL

          -  A screening TSH consistent with Hypothyroidism

          -  Significant renal disease or acute nephritis

          -  Significant myocardial disease or diagnosed coronary artery disease

          -  Significant respiratory disease

          -  History of psychosis, seizure disorder, abnormal electroencephalogram or brain damage
             with significant persisting neurological deficit.

          -  Clinically active hepatitis as evidenced by clinical jaundice or Grade 2 or higher
             liver function test abnormalities.

          -  Hepatic cirrhosis or decompensated chronic liver disease.

          -  Diabetes or current hypothyroidism.

          -  Concurrent treatment with immunomodulatory drugs, or exposure to any immunomodulatory
             drug in past 16 weeks.

          -  Recent exposure (within the preceding 8 weeks) to any vaccine.

          -  Pregnant or breastfeeding women. Women of childbearing potential must have a negative
             serum pregnancy test at screening and agree to use a double-barrier method of
             contraception throughout the study period.

          -  Significant substance use, which in the opinion of the investigator, is likely to
             interfere with the conduct of the study.

          -  Prior or current use of disulfiram, vorinostat or other experimental agent used with
             the intent to perturb the HIV-1 viral reservoir

          -  Current use of an antiretroviral regimen which does not include either efavirenz or a
             protease inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Deeks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Californa, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julian Elliott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 12, 2013</study_first_submitted>
  <study_first_submitted_qc>September 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2013</study_first_posted>
  <results_first_submitted>December 8, 2018</results_first_submitted>
  <results_first_submitted_qc>April 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 5, 2020</results_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Steven Deeks</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Latent reservoir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disulfiram</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of 34 participants screened for eligibility, we recruited 30 participants at The Alfred Hospital (Melbourne, VIC, Australia) and the San Francisco General Hospital (San Francisco, CA, USA) between September 24, 2013, and March 31, 2014.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Disulfiram 500mg</title>
          <description>500mg disulfiram by mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
        </group>
        <group group_id="P2">
          <title>Disulfiram 1000mg</title>
          <description>1000mg disulfiram by mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
        </group>
        <group group_id="P3">
          <title>Disulfiram 2000mg</title>
          <description>2000mg disulfiram per mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Disulfiram 500mg</title>
          <description>500mg disulfiram by mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
        </group>
        <group group_id="B2">
          <title>Disulfiram 1000mg</title>
          <description>1000mg disulfiram by mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
        </group>
        <group group_id="B3">
          <title>Disulfiram 2000mg</title>
          <description>2000mg disulfiram per mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="34" upper_limit="63"/>
                    <measurement group_id="B2" value="54" lower_limit="40" upper_limit="65"/>
                    <measurement group_id="B3" value="51" lower_limit="26" upper_limit="67"/>
                    <measurement group_id="B4" value="53" lower_limit="26" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cell-associated HIV RNA</title>
        <description>Fold change cell-associated HIV RNA in Total CD4 T-Cells.</description>
        <time_frame>Baseline and 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Disulfiram 500mg</title>
            <description>500mg disulfiram by mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Disulfiram 1000mg</title>
            <description>1000mg disulfiram by mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Disulfiram 2000mg</title>
            <description>2000mg disulfiram per mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cell-associated HIV RNA</title>
          <description>Fold change cell-associated HIV RNA in Total CD4 T-Cells.</description>
          <units>Fold change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.3" upper_limit="2.2"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.6" upper_limit="2.4"/>
                    <measurement group_id="O3" value="1.6" lower_limit="1.2" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma HIV RNA</title>
        <description>Fold change in plasma HIV RNA levels from baseline through day 3</description>
        <time_frame>Baseline and 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Disulfiram 500mg</title>
            <description>500mg disulfiram by mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Disulfiram 1000mg</title>
            <description>1000mg disulfiram by mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Disulfiram 2000mg</title>
            <description>2000mg disulfiram per mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma HIV RNA</title>
          <description>Fold change in plasma HIV RNA levels from baseline through day 3</description>
          <units>Fold change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.36" upper_limit="3.4"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.18" upper_limit="1.7"/>
                    <measurement group_id="O3" value="1.22" lower_limit="0.32" upper_limit="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proviral HIV DNA</title>
        <description>Fold change in HIV DNA levels between Baseline and Day 30</description>
        <time_frame>Baseline and 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Disulfiram 500mg</title>
            <description>500mg disulfiram by mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Disulfiram 1000mg</title>
            <description>1000mg disulfiram by mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Disulfiram 2000mg</title>
            <description>2000mg disulfiram per mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Proviral HIV DNA</title>
          <description>Fold change in HIV DNA levels between Baseline and Day 30</description>
          <units>Fold change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="0.89" upper_limit="1.28"/>
                    <measurement group_id="O2" value="0.83" lower_limit="0.60" upper_limit="1.15"/>
                    <measurement group_id="O3" value="0.91" lower_limit="0.77" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Disufiram Pharmacokinetics</title>
        <description>Plasma concentrations of disulfiram were measured on dosing day 1 (hours 0, 2, and 6), day 2 (hour 0), and day 3 (hours 0, 2, and 6), as well as on postdosing days 4, 8, and 31. The area under the curve (AUC) levels over 72 hours was estimated.</description>
        <time_frame>31 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Disulfiram 500mg</title>
            <description>500mg disulfiram by mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
          </group>
          <group group_id="O2">
            <title>Disulfiram 1000mg</title>
            <description>1000mg disulfiram by mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
          </group>
          <group group_id="O3">
            <title>Disulfiram 2000mg</title>
            <description>2000mg disulfiram per mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Disufiram Pharmacokinetics</title>
          <description>Plasma concentrations of disulfiram were measured on dosing day 1 (hours 0, 2, and 6), day 2 (hour 0), and day 3 (hours 0, 2, and 6), as well as on postdosing days 4, 8, and 31. The area under the curve (AUC) levels over 72 hours was estimated.</description>
          <units>mg-hour/liter</units>
          <param>Mean</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3,186" lower_limit="3,140" upper_limit="3,281"/>
                    <measurement group_id="O2" value="8,386" lower_limit="7,149" upper_limit="12,861"/>
                    <measurement group_id="O3" value="22,331" lower_limit="18,481" upper_limit="35,102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were monitored in an outpatient clinic during the first 6 hours post-dose on days 1 and 3. At each visit, subjects were assessed for any new symptoms and vital signs. A complete blood count and complete metabolic panel were performed during screening, and then at Days 1, 2, 3, 4, 8 and 31. No evaluations were made after Day 31.</time_frame>
      <desc>The grading system for drug toxicities is located in the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004 (Clarification, August 2009), which can be found on the DAIDS RSC Web Site (http://rsc.tech-res.com/safetyandpharmacovigilance/.)</desc>
      <group_list>
        <group group_id="E1">
          <title>Disulfiram 500mg</title>
          <description>500mg disulfiram by mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
        </group>
        <group group_id="E2">
          <title>Disulfiram 1000mg</title>
          <description>1000mg disulfiram by mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
        </group>
        <group group_id="E3">
          <title>Disulfiram 2000mg</title>
          <description>2000mg disulfiram per mouth per day for 3 days
Disulfiram: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased aspartate aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven G. Deeks</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>4156064082 ext 404</phone>
      <email>Steven.Deeks@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

